Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Thoracic Surgery ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA A Cancer J Clin. 2021; 71: 209-249
- Impact of sites of metastatic dissemination on survival in advanced gastroesophageal adenocarcinoma.Oncology. 2022; 100: 439-448
- Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial.Lancet Oncol. 2015; 16: 1090-1098
- Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a ra.Lancet. 2019; 393: 1948-1957
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study.Lancet. 2021; 398: 759-771
- PET-guided treatment algorithms in oesophageal cancer: the promise of the near future.J Thorac Dis. 2017; 9: 2736-2739
- The epidemic of oesophageal carcinoma: where are we now?.Cancer Epidemiol. 2016; 41: 88-95
- the global landscape of esophageal squamous cell carcinoma and esophageal adenocarcinoma incidence and mortality in 2020 and projections to 2040: new estimates from GLOBOCAN 2020.Gastroenterology. 2022; 163: 649-658.e2
- Squamous cell carcinoma and adenocarcinoma of the lower third of the esophagus and gastric cardia: similarities and differences.Dis Esophagus. 2002; 15: 290-295
- Esophageal carcinoma.N Engl J Med. 2015; 372: 1472-1473
- Integrated genomic characterization of oesophageal carcinoma.Nature. 2017; 541: 169-174
- The tumour immune microenvironment in oesophageal cancer.Br J Cancer. 2021; 125: 479-494
- Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: The Randomized Controlled CROSS Trial.J Clin Oncol. 2021; 39: 1995-2004
- Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781.J Clin Oncol. 2008; 26: 1086-1092
- Randomized, phase ii study prospectively evaluating treatment of metastatic esophageal, gastric, or gastroesophageal cancer by gene expression of ERCC1: SWOG S1201.J Clin Oncol. 2020; 38: 472-479
- Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: The NEOCRTEC5010 Randomized Clinical Trial.JAMA Surg. 2021; 156: 721-729
- Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).J Clin Oncol. 2021; 39: 4004
- ESOPEC: prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286).BMC Cancer. 2016; 16: 503
- Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus.J Clin Oncol. 2005; 23: 2310-2317
- Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102.J Clin Oncol. 2007; 25: 1160-1168
- Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer.N Engl J Med. 2021; 384: 1191-1203
- First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial.Lancet (London, England). 2021; 398: 27-40
- Immunotherapy in patients with locally advanced esophageal carcinoma: ASCO treatment of locally advanced esophageal carcinoma guideline rapid recommendation update.J Clin Oncol. 2021; 39: 3182-3184
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma.N Engl J Med. 2018; 378: 1789-1801
- Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.Lancet. 2021; 398: 1344-1357
- Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma.N Engl J Med. 2021; 384: 2102-2114
- Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease.Cancer Discov. 2016; 6: 1382-1399
- Molecular and biochemical aspects of the PD-1 checkpoint pathway.N Engl J Med. 2016; 375 (Longo DL, ed): 1767-1778
- DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells.Nat Commun. 2017; 8: 1751
- Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1).Eur J Cancer. 2021; 144: 232-241
- Neoadjuvant pembrolizumab and chemotherapy in resectable esophageal cancer: an Open-Label, Single-Arm Study (PEN-ICE).Front Immunol. 2022; 13 (849984)
- KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma.Future Oncol. 2021; 17: 1143-1153
- SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy.J Clin Oncol. 2022; 40: TPS374
- TIGIT in cancer immunotherapy.J Immunother Cancer. 2020; 8 (e000957)
- Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study.Lancet Oncol. 2022; 23: 781-792
- Surgical and pathological outcome, and pathological regression, in patients receiving perioperative atezolizumab in combination with FLOT chemotherapy versus FLOT alone for resectable esophagogastric adenocarcinoma: Interim results from DANTE, a randomize.J Clin Oncol. 2022; 40: 4003
- MATTERHORN: efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—a randomized, double-blind, placebo-controlled, phase 3 study.J Clin Oncol. 2021; 39: TPS4151
- A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: A trial of the ECOG-ACRIN Cancer Research Group (EA2174).J Clin Oncol. 2020; 38: TPS4651
- ATTRACTION-05 (ONO-4538-38/BMS CA209844): a randomized, multicenter, double-blind, placebo- controlled Phase 3 study of Nivolumab (Nivo) in combination with adjuvant chemotherapy in pStage III gastric and esophagogastric junction (G/EGJ) cancer.Ann Oncol. 2017; 28: v266-v267
- Landscape of microsatellite instability across 39 cancer types.JCO Precis Oncol. 2017; 2017https://doi.org/10.1200/PO.17.00073
- From tumor immunology to immunotherapy in gastric and esophageal cancer.Int J Mol Sci. 2018; 20: 13
- Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer.J Clin Oncol. 2019; 37: 3392-3400
- Neoadjuvant nivolumab plus ipilimumab and adjuvant nivolumab in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma: The GERCOR NEONIPIGA Phase II Study.J Clin Oncol. 2023; 41: 255-265
- Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer: results of a multicentre prospective study.Eur J Nucl Med Mol Imaging. 2009; 36: 354-361
- Clinical utility of 18F-Fluorodeoxyglucose positron emission tomography/computed tomography in the staging of patients with potentially resectable esophageal cancer.J Thorac Oncol. 2013; 8: 1563-1569
- Value and limitation of 18F-FDG PET/CT in the staging of thoracic esophageal cancer.J Nucl Med. 2011; 52: 1842
- Systematic review and meta-analysis of the accuracy of 18F-FDG PET/CT for detection of regional lymph node metastasis in esophageal squamous cell carcinoma.J Thorac Dis. 2018; 10: 6066-6076
- Interim 18 F-FDG-PET/CT during chemo-radiotherapy in the management of oesophageal cancer patients. A systematic review.Radiother Oncol. 2017; 125: 200-212
- Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.J Clin Oncol. 2001; 19: 3058-3065
- Metabolic imaging predicts response, survival, and recurrence in adenocarcinomas of the esophagogastric junction.J Clin Oncol. 2006; 24: 4692-4698
- PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.Lancet Oncol. 2007; 8: 797-805
- 18 F-FDG PET–guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II Trial.J Nucl Med. 2011; 52: 1189-1196
- Preoperative cisplatin, fluorouracil, and docetaxel with or without radiotherapy after poor early response to cisplatin and fluorouracil for resectable oesophageal adenocarcinoma (AGITG DOCTOR): results from a multicentre, randomised controlled phase II t.Ann Oncol. 2020; 31: 236-245
- Metabolic response assessment and PET-guided treatment of esophageal cancer.Ann Oncol. 2020; 31: 163-164
- Randomized Phase II Study of PET response–adapted combined modality therapy for esophageal cancer: mature results of the CALGB 80803 (Alliance) trial.J Clin Oncol. 2021; 39: 2803-2815
- The value of 18F-FDG PET before and after induction chemotherapy for the early prediction of a poor pathologic response to subsequent preoperative chemoradiotherapy in oesophageal adenocarcinoma.Eur J Nucl Med Mol Imaging. 2017; 44: 71-80
- 18-fluorodeoxy-glucose positron emission computed tomography as predictive of response after chemoradiation in oesophageal cancer patients.Eur J Cancer. 2015; 51: 2545-2552
- 18F-FDG PET/CT metrics are correlated to the pathological response in esophageal cancer patients treated with induction chemotherapy followed by neoadjuvant chemo-radiotherapy.Front Oncol. 2020; 10: 1-11
Article info
Publication history
Published online: February 26, 2023
Publication stage
In Press Corrected ProofIdentification
Copyright
© 2023 Elsevier Inc. All rights reserved.
